To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

We did not, however, imagine that over the intervening months, vaccination in general, and mRNA vaccines in particular, would escalate into a political wedge issue that threatens to undermine the ...

Beyond Khorana score 2: Molecular correlates of venous thromboembolism in pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

Introduction: The first vaccines approved against SARS-CoV-2, mRNA-1273 and BNT162b2, utilized mRNA platforms. However, little is known about the proteomic markers and pathways associated with host ...

It's therefore worth looking at Moderna's earnings history below. Of course, the future is what really matters. NasdaqGS:MRNA Earnings and Revenue Growth January 22nd 2025 Investors should note ...

Moderna (NASDAQ:MRNA) was among the notable gainers on Wednesday after Oracle (NYSE:ORCL) Chairman Larry Ellison highlighted the AI's potential in the development of messenger RNA-based cancer ...

The project, which could cost up to $500 billion, was described by Trump as the "largest AI infrastructure project in history ... detect cancers and customize mRNA vaccines to treat them within ...

The firm's mRNA technology was rapidly validated with ... In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current ...